Hugo E. Velázquez, MD

home / authors / hugo-e-velzquez-md

Articles

Diffuse Hepatic Infiltration by Metastatic Melanoma

Hugo E. Velázquez, MD;Francisco J. Castro-Alonso, MD;Christianne Bourlon, MD, MS;Alejandro Gabutti, MD;Cecilia Gallegos, MD;María T. Bourlon, MD, MSc, FASCO

July 16th 2019

Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.

Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?

María T. Bourlon, MD, MSc, FASCO;Hugo E. Velázquez, MD;Rodrigo Luna-Santiago, MD;Sara Vázquez-Manjarrez, MD;Christianne Bourlon, MD, MHSc

February 15th 2018

A 67-year-old man, a former smoker, presented with gross hematuria. A CT urogram showed a bladder tumor in the anterior wall and multiple enlarged retroperitoneal lymph nodes. Two vertebral metastases were seen on a bone scan. He underwent a transurethral resection of the bladder, and the pathology report revealed muscle-invasive urothelial carcinoma.